コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 d anti-phosphatidyl-serine) and 1 in plasma (lupus anticoagulant).
2 reviously reported to be associated with the lupus anticoagulant.
3 n increased thrombotic risk in patients with lupus anticoagulant.
4 differed in sensitivity to the presence of a lupus anticoagulant.
5 he clotting test is used in the diagnosis of lupus anticoagulants.
6 mbin times is invalid for some patients with lupus anticoagulants.
7 monitored with a test that is insensitive to lupus anticoagulants.
10 ody was analyzed for its binding properties, lupus anticoagulant activity, and pathophysiologic activ
15 present with thrombosis and are positive for lupus anticoagulant and ACAs have similar clinical prese
17 6.6%) were positive for aPL because they had lupus anticoagulant and/or high titer of anticardiolipin
19 n antigen specificities of autoantibodies in lupus anticoagulants and the mechanisms by which these a
20 bodies including anticardiolipin antibodies, lupus anticoagulants, and anti-beta(2) glycoprotein-1-sp
22 I, fibrinogen, lipoprotein(a), homocysteine, lupus anticoagulant, anticardiolipin antibodies and geno
23 ecurrent fetal loss, and the presence of the lupus anticoagulant, anticardiolipin antibodies, or anti
24 All patients who had positive results of lupus anticoagulant, anticardiolipin, and anti-beta(2)-g
26 owever, establish that the autoantibodies in lupus anticoagulants are not directed against "native" a
27 n enzyme-linked immunosorbent assay (ELISA), lupus anticoagulant assays, and syphilis screening in ch
30 ossibly the same epitope associated with the lupus anticoagulant, defined a small subset of children
31 annexin V, stands in marked contrast to the "lupus anticoagulant effect" previously described in thes
35 ting 151 patients with persistently positive lupus anticoagulant (LA) for a median period of 8.2 year
38 line predictors of APOs included presence of lupus anticoagulant (LAC) (odds ratio [OR], 8.32 [CI, 3.
39 glycerides (all P < 0.0001), and presence of lupus anticoagulant (LAC) (P = 0.045) were associated wi
40 pid antibodies under the perception that the lupus anticoagulant (LAC) is prevalent in this populatio
41 e Caucasian ethnicity, smoking, alcohol use, lupus anticoagulant (LAC) positivity, and renal involvem
42 dsDNA], anti-Sm, anti-Ro, anti-La, anti-RNP, lupus anticoagulant (LAC), and anticardiolipin antibody
43 esence of antiphospholipid antibodies (aPL), lupus anticoagulant (LAC), anti-beta2GPI antibody, and t
44 ence of anti-phospholipid (PL) Ab, including lupus anticoagulants (LAC) and/or anticardiolipin Ab (aC
47 well as elevated anticardiolipin antibodies, lupus anticoagulant, or a history compatible with antiph
51 significantly associated with positivity for lupus anticoagulant (P < 0.0001) and anticardiolipin ant
52 trols, CVD patients were more likely to have lupus anticoagulant (P = 0.03), but less likely to be re
55 on laboratory and clinical manifestations of lupus anticoagulants, the pathogenetic mechanisms involv
56 id syndrome includes elevation of either the lupus anticoagulant titer or the anticardiolipin antibod
60 s) for oral anticoagulation in patients with lupus anticoagulants who sustain a thromboembolic event
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。